Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib in Renal Cell Carcinoma
NCT00502307Phase 2Completed
- Sponsor
- AVEO Oncology
- Start
- Oct 2007
- Primary completion
- Aug 2010
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Tivozanib with Placebo (2 arms). Primary endpoints: Number of Subjects With Adverse Events (AEs)/Serious AEs (SAEs) at 28 weeks, Objective Response Rate at 16 weeks and 1 more. Started Oct 2007; status: completed.
02
Drugs
tivozanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00502307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00502307.